TAO Kinase 3 Overexpression Is a Poor Prognosis Marker for Lung Adenocarcinoma and Predicts Paclitaxel Resistance
AbstractHigh expression of TAOK3 has been observed in several cancers, but very little about TAOK3-involved mechanisms has been reported. In this study, we investigated the role of TAOK3 in the therapeutic effect of paclitaxel treatment. Protein expression of TAOK3 was evaluated among 121 patients by using immunohistochemical staining. TAOK3 expression was estimated by analyzing the gene’s expression and its correlation with the IC50 of paclitaxel in cells. The expression of TAOK3 in lung cancer was highly correlated with poor overall survival, progression-free survival, and recurrence rate in lung cancer patients. The expression level of TAOK3 was positively correlated with paclitaxel resistance in the lung cancer cell lines. The depletion of TAOK3 could enhance the sensitivity of paclitaxel in lung cancer and vice versa. TAOK3 expression is associated with paclitaxel-resistance and could be a clinical predictor for disease recurrence and a potential therapeutic target in lung cancer.